Workflow
Johnson & Johnson (JNJ) Gains FDA Nod for Subcutaneous Tremfya in Ulcerative Colitis
强生强生(US:JNJ) Yahoo Finance·2025-09-24 07:02

In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Johnson & Johnson is one of them. Johnson & Johnson (NYSE:JNJ), a global healthcare leader, continues to strengthen its pharmaceuticals and immunology portfolio while delivering strong stock performance in 2025. This month, the company received FDA approval for a subcutaneous induction regimen of Tremfya (guselkumab) to treat adults with ulcerative colitis. As the first and only IL-23 inhibitor with a ...